|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.02 USD | -1.81% |
|
-9.71% | +93.35% |
| 07-22 | What Bundibugyo Ebola vaccines and treatments are under development | RE |
| 07-22 | Biotech experts want FDA drug reviews based on science, not politics | RE |
| Market Cap | 22.62B 19.9B 18.49B 17B 31.88B 2,191B 32.46B 221B 86.22B 1,069B 84.94B 83.1B 3,708B | P/E 2026 * |
-6.59x | P/E 2027 * | -12x |
|---|---|---|---|---|---|
| Enterprise Value | 19.22B 16.9B 15.7B 14.44B 27.08B 1,861B 27.57B 188B 73.24B 908B 72.15B 70.59B 3,149B | EV / Sales 2026 * |
9.17x | EV / Sales 2027 * | 8.06x |
| Free-Float |
92.69% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Moderna, Inc.
| 1 day | -1.81% | ||
| 1 week | -9.71% | ||
| Current month | -18.58% | ||
| 1 month | -6.52% | ||
| 3 months | +7.89% | ||
| 6 months | +17.06% | ||
| Current year | +93.35% |
| 1 week | 56.28 |  | 62.43 |
| 1 month | 56.28 | | 85.6 |
| Current year | 29.81 | | 85.6 |
| 1 year | 22.28 | | 85.6 |
| 3 years | 22.28 | | 170.47 |
| 5 years | 22.28 | | 497.49 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 28/02/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 05/09/2022 |
Stephen Hoge
PSD | President | 50 | 31/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 31/01/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 28/02/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 10/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 15/07/26 | Fiscal year | Chairperson | 160,008 | 0.0403% | ||
| 08/07/26 | Free | Director | 14,766 | 0.0037% | ||
| 05/07/26 | Free | Executive/Senior Manager | 57,022 | 0.0144% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.81% | -9.71% | +64.46% | -54.90% | 22.62B | |
| +0.11% | -3.98% | +13.89% | -11.26% | 66.32B | |
| +0.62% | +2.17% | +36.67% | +200.29% | 52.6B | |
| +0.51% | +37.90% | +37.90% | +37.90% | 43.27B | |
| -1.32% | -7.38% | -57.63% | -57.10% | 38.64B | |
| +1.46% | -3.97% | +53.17% | -27.51% | 29.62B | |
| +0.78% | +0.03% | +65.07% | +81.90% | 23.31B | |
| -1.21% | +1.12% | +1.98% | +170.93% | 20.22B | |
| -1.03% | -1.86% | +60.48% | +121.72% | 16.29B | |
| +0.33% | +3.28% | +79.54% | +142.98% | 16.26B | |
| Average | -0.16% | -2.28% | +35.55% | +60.50% | 32.92B | |
| Weighted average by Cap. | -0.01% | -2.31% | +27.74% | +51.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.1B 1.84B 1.71B 1.57B 2.95B 203B 3.01B 20.47B 7.98B 98.96B 7.87B 7.7B 343B | 2.55B 2.24B 2.08B 1.92B 3.6B 247B 3.66B 24.93B 9.72B 121B 9.58B 9.37B 418B |
| Net income | -3.41B -3B -2.79B -2.56B -4.8B -330B -4.89B -33.31B -12.99B -161B -12.8B -12.52B -559B | -1.85B -1.63B -1.51B -1.39B -2.61B -179B -2.65B -18.07B -7.05B -87.35B -6.94B -6.79B -303B |
| Net Debt | -3.41B -3B -2.78B -2.56B -4.8B -330B -4.89B -33.28B -12.98B -161B -12.79B -12.51B -558B | -2.05B -1.81B -1.68B -1.54B -2.89B -199B -2.95B -20.06B -7.82B -96.98B -7.71B -7.54B -336B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/07/26 | US$57.02 | -1.81% | 4,695,588 |
| 22/07/26 | US$58.07 | -2.67% | 3,780,416 |
| 21/07/26 | US$59.66 | +0.29% | 4,357,386 |
| 20/07/26 | US$59.49 | -3.77% | 4,967,920 |
| 17/07/26 | US$61.82 | -2.11% | 4,551,991 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
